Alexion Pharmaceuticals Agrees to $21.5 Million Settlement With SEC in Bribery Case

Alexion Pharmaceuticals (NASDAQ: ALXN) is reaching into its coffers to settle charges leveled against it by the Securities and Exchange Commission. The company will hand over a total of roughly $21.5 million in disgorgement, civil penalties, and pre-judgment interest to the regulator.

The SEC alleges that the company violated the Foreign Corrupt Practices Act, the federal anti-corruption law that bars U.S. corporations and citizens from bribing government officials abroad.

Image source: Getty Images.

Continue reading

Source Fool.com